Tamara Mills

Tamara Mills is a seasoned professional with extensive experience in commercializing innovative medical technologies across the United States, Japan, Brazil, Europe, and Australia.

Throughout her career, Tamara has held executive positions in both publicly listed and private companies, demonstrating a strong track record in alternative asset portfolio management and leading complex pharmaceutical and medical device products from concept to commercialization.

Tamara's expertise extends to the fields of diagnostic and therapeutic technology development, as evidenced by her past roles as Chair of Health Policy, Regulatory and Reimbursement committee for CORAR and key leadership positions in industry organizations like MITA.

Currently, Tamara serves as the Principal at Predict Ltd UK, offering strategic and transactional consultancy in the Diagnostic Imaging, Nuclear Medicine, and Radiotherapeutics sectors.

Tamara also has a remarkable entrepreneurial mindset, having founded and led health technology companies such as Glucotek and De Motu Cordis, focused on enhancing healthcare through innovative design and science.

Her involvement in early-stage technology investments includes advising venture capital firms and private investors, and as the Managing Director of ImpactXHealth, she plays a pivotal role in fostering growth and strategic investments in the health innovation ecosystem.

Tamara's educational background is diverse, including studies in New Venture Leadership, Business Administration, Health Economics, and Impact Investment Program from reputable institutions such as MIT, Concordia University, and Harvard School of Public Health.

She is also well-versed in nuclear medicine, having pursued a Master's degree in Applied Science in the field.

In terms of organizational involvement, Tamara has held various leadership positions at ImpactXHealth, Ferronova, BWX Technologies, Inc., and other entities, showcasing her versatile skill set and extensive network within the industry.